Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1985 Mar;27(3):285–290. doi: 10.1128/aac.27.3.285

Pharmacokinetics of tobramycin and gentamicin in abusers of intravenous drugs.

C H King, R J Creger, J J Ellner
PMCID: PMC176262  PMID: 3994344

Abstract

The kinetics of aminoglycoside elimination were determined in 18 hospitalized narcotics abusers receiving gentamicin or tobramycin for treatment of severe infection. Rapid aminoglycoside elimination (requiring doses of greater than 5 mg/kg per day to maintain adequate drug levels) was noted in 12 of the 18 patients (18 of 27 clearance studies). Patients found to have rapid elimination were younger (P less than 0.01) and had larger drug distribution volumes (P less than 0.005), greater measured creatinine clearances (P less than 0.05), and lower creatinine levels in serum (P less than 0.001) than those with normal elimination. Nevertheless, by regression analysis, age, creatinine levels in serum, creatinine clearances, and drug distribution volumes proved to be unreliable predictors of individual aminoglycoside clearance. Measured drug half-life in serum appeared to be the only reliable predictor of drug clearance (r = 0.93). Patients with rapid drug elimination had aminoglycoside clearances 16 to 43% greater than measured creatinine clearances, suggesting an extraglomerular route of drug elimination. We conclude that in drug abuse patients a significant and clinically unpredictable interpatient variation occurs in aminoglycoside elimination and that accurate serum kinetics are needed to determine therapeutic dosing. In addicts younger than 35 years, with a creatinine level of less than 1.0 mg/100 ml in serum, the risk of inadequate therapy is high if standard dosing guidelines are followed. For this group, initial dosing of 8 mg/kg per day, with a drug half-life determination on the first dose, is recommended. Pharmacokinetic analysis is critical for all drug abusers treated with aminoglycosides for serious infection.

Full text

PDF
285

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anderson E. T., Young L. S., Hewitt W. L. Simultaneous antibiotic levels in "breakthrough" gram-negative rod bacteremia. Am J Med. 1976 Oct;61(4):493–497. doi: 10.1016/0002-9343(76)90328-4. [DOI] [PubMed] [Google Scholar]
  2. Archer G., Fekety F. R., Jr Experimental endocarditis due to Pseudomonas aeruginosa. II. Therapy with carbenicillin and gentamicin. J Infect Dis. 1977 Sep;136(3):327–335. doi: 10.1093/infdis/136.3.327. [DOI] [PubMed] [Google Scholar]
  3. Bauer L. A., Blouin R. A. Influence of age on tobramycin pharmacokinetics in patients with normal renal function. Antimicrob Agents Chemother. 1981 Nov;20(5):587–589. doi: 10.1128/aac.20.5.587. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Chan R. A., Benner E. J., Hoeprich P. D. Gentamicin therapy in renal failure: a nomogram for dosage. Ann Intern Med. 1972 May;76(5):773–778. doi: 10.7326/0003-4819-76-5-773. [DOI] [PubMed] [Google Scholar]
  5. Cherubin C., McCusker J., Baden M., Kavaler F., Amsel Z. Epidemiology of death in narcotic addicts. Am J Epidemiol. 1972 Jul;96(1):11–22. doi: 10.1093/oxfordjournals.aje.a121428. [DOI] [PubMed] [Google Scholar]
  6. Cockcroft D. W., Gault M. H. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31–41. doi: 10.1159/000180580. [DOI] [PubMed] [Google Scholar]
  7. Gyselynck A. M., Forrey A., Cutler R. Pharmacokinetics of gentamicin: distribution and plasma and renal clearance. J Infect Dis. 1971 Dec;124 (Suppl):S70–S76. doi: 10.1093/infdis/124.supplement_1.s70. [DOI] [PubMed] [Google Scholar]
  8. Hau T., Kallick C. A. Surgical infections in drug addicts. World J Surg. 1980 Jul;4(4):403–413. doi: 10.1007/BF02393159. [DOI] [PubMed] [Google Scholar]
  9. JAO R. L., JACKSON G. G. GENTAMICIN SULFATE, NEW ANTIBIOTIC AGAINST GRAM-NEGATIVE BACILLI. LABORATORY, PHARMACOLOGICAL, AND CLINICAL EVALUATION. JAMA. 1964 Sep 14;189:817–822. doi: 10.1001/jama.1964.03070110019004. [DOI] [PubMed] [Google Scholar]
  10. Jackson G. G., Riff L. J. Pseudomonas bacteremia: pharmacologic and other bases for failure of treatment with gentamicin. J Infect Dis. 1971 Dec;124 (Suppl):S185–S191. doi: 10.1093/infdis/124.supplement_1.s185. [DOI] [PubMed] [Google Scholar]
  11. Kaye D., Levison M. E., Labovitz E. D. The unpredictability of serum concentrations of gentamicin: pharmacokinetics of gentamicin in patients with normal and abnormal renal function. J Infect Dis. 1974 Aug;130(2):150–154. doi: 10.1093/infdis/130.2.150. [DOI] [PubMed] [Google Scholar]
  12. Kirby W. M., Clarke J. T., Libke R. D., Regamey C. Clinical pharmacology of amikacin and kanamycin. J Infect Dis. 1976 Nov;134(Suppl):S312–S315. doi: 10.1093/infdis/135.supplement_2.s312. [DOI] [PubMed] [Google Scholar]
  13. Noone P., Parsons T. M., Pattison J. R., Slack R. C., Garfield-Davies D., Hughes K. Experience in monitoring gentamicin therapy during treatment of serious gram-negative sepsis. Br Med J. 1974 Mar 16;1(5906):477–481. doi: 10.1136/bmj.1.5906.477. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Pickering L. K., Gearhart P. Effect of time and concentration upon interaction between gentamicin, tobramycin, Netilmicin, or amikacin and carbenicillin or ticarcillin. Antimicrob Agents Chemother. 1979 Apr;15(4):592–596. doi: 10.1128/aac.15.4.592. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Regamey C., Gordon R. C., Kirby W. M. Comparative pharmacokinetics of tobramycin and gentamicin. Clin Pharmacol Ther. 1973 May-Jun;14(3):396–403. doi: 10.1002/cpt1973143396. [DOI] [PubMed] [Google Scholar]
  16. Reyes M. P., Brown W. J., Lerner A. M. Treatment of patients with pseudomonas endocarditis with high dose aminoglycoside and carbenicillin therapy. Medicine (Baltimore) 1978 Jan;57(1):57–67. doi: 10.1097/00005792-197801000-00004. [DOI] [PubMed] [Google Scholar]
  17. Reyes M. P., Lerner A. M. Current problems in the treatment of infective endocarditis due to Pseudomonas aeruginosa. Rev Infect Dis. 1983 Mar-Apr;5(2):314–321. doi: 10.1093/clinids/5.2.314. [DOI] [PubMed] [Google Scholar]
  18. Sapira J. D., Ball J. C., Penn H. Causes of death among institutionalized narcotic addicts. J Chronic Dis. 1970 Apr;22(11):733–742. doi: 10.1016/0021-9681(70)90049-4. [DOI] [PubMed] [Google Scholar]
  19. Sawchuk R. J., Zaske D. E. Pharmacokinetics of dosing regimens which utilize multiple intravenous infusions: gentamicin in burn patients. J Pharmacokinet Biopharm. 1976 Apr;4(2):183–195. doi: 10.1007/BF01086153. [DOI] [PubMed] [Google Scholar]
  20. Siber G. R., Echeverria P., Smith A. L., Paisley J. W., Smith D. H. Pharmacokinetics of gentamicin in children and adults. J Infect Dis. 1975 Dec;132(6):637–651. doi: 10.1093/infdis/132.6.637. [DOI] [PubMed] [Google Scholar]
  21. Smithivas T., Hyams P. J., Rahal J. J., Jr Gentamicin and ampicillin in human bile. J Infect Dis. 1971 Dec;124 (Suppl):S106–S108. doi: 10.1093/infdis/124.supplement_1.s106. [DOI] [PubMed] [Google Scholar]
  22. Trollfors B., Alestig K., Krantz I., Norrby R. Quantitative nephrotoxicity of gentamicin in nontoxic doses. J Infect Dis. 1980 Mar;141(3):306–309. doi: 10.1093/infdis/141.3.306. [DOI] [PubMed] [Google Scholar]
  23. Wilson T. W., Mahon W. A., Inaba T., Johnson G. E., Kadar D. Elimination of tritiated gentamicin in normal human subjects and in patients with severely impaired renal function. Clin Pharmacol Ther. 1973 Sep-Oct;14(5):815–822. doi: 10.1002/cpt1973145815. [DOI] [PubMed] [Google Scholar]
  24. Zaske D. E., Cipolle R. J., Rotschafer J. C., Solem L. D., Mosier N. R., Strate R. G. Gentamicin pharmacokinetics in 1,640 patients: method for control of serum concentrations. Antimicrob Agents Chemother. 1982 Mar;21(3):407–411. doi: 10.1128/aac.21.3.407. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Zaske D. E., Cipolle R. J., Strate R. G., Malo J. W., Koszalka M. F., Jr Rapid gentamicin elimination in obstetric patients. Obstet Gynecol. 1980 Nov;56(5):559–564. [PubMed] [Google Scholar]
  26. Zaske D. E., Sawchuk R. J., Gerding D. N., Strate R. G. Increased dosage requirements of gentamicin in burn patients. J Trauma. 1976 Oct;16(10):824–828. doi: 10.1097/00005373-197610000-00014. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES